Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DM199 in Healthy Subjects and Type 2 Diabetes
NCT01845064Phase 2Completed
- Sponsor
- DiaMedica Therapeutics
- Start
- Apr 2013
- Primary completion
- Sep 2014
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of rinvecalinase alfa in type 2 diabetes mellitus (T2DM), sponsored by DiaMedica Therapeutics. Started Apr 2013; status: completed.
02
Drugs
rinvecalinase alfa
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01845064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01845064.